Trials / Unknown
UnknownNCT03461627
Salmeterol Xinafoate and Fluticasone Propinate Powder for Inhalation for Asthma
Salmeterol Xinafoate and Fluticasone Propinate Powder for Inhalation for Asthma: A Randomized, Double-blind, Double-dummy, Positive-controlled, Parallel-group Trail
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
assess the efficacy and safety of Salmeterol Xinafoate and Fluticasone Propinate Powder for inhalation (50ug/250ug) in combination with seretide to patients with Asthma. a randomized, double-blind, double-dummy, positive-controlled, parallel-group trail.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Salmeterol Xinafoate and Fluticasone Propinate Powder | 50ug/250ug 1 puff twice a day for 4 weeks |
| DRUG | Seretide | 50ug/250ug 1 puff twice a day for 4 weeks |
Timeline
- Start date
- 2017-04-01
- Primary completion
- 2018-10-31
- Completion
- 2018-10-31
- First posted
- 2018-03-12
- Last updated
- 2018-03-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03461627. Inclusion in this directory is not an endorsement.